Bone Biologics Net Income Over Time
| BBLG Stock | USD 1.30 0.01 0.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bone Biologics Performance and Bone Biologics Correlation. Bone |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Bone Biologics Corp and related stocks such as Bluejay Diagnostics, Talis Biomedical Corp, and Nuwellis Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BJDX | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (1.1 M) | (3.7 M) | (9.2 M) | (10 M) | (9.5 M) |
| NUWE | (1 M) | (16.2 M) | (14.1 M) | (21.8 M) | (25.6 M) | (26.6 M) | (15.8 M) | (13.4 M) | (17 M) | (18.1 M) | (15.8 M) | (19.6 M) | (14.5 M) | (20.2 M) | (21.2 M) |
| HSCS | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (2.6 M) | (4.6 M) | (490.9 M) | (6.6 M) | (6.9 M) |
| TIVC | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (8.5 M) | (10.1 M) | (8.2 M) | (8.7 M) |
| VVOS | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (10.9 M) | (8.8 M) | (20.3 M) | (22.7 M) | (13.6 M) | (14.3 M) |
| RPID | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (37.1 M) | (73.5 M) | (60.8 M) | (52.5 M) | (55.1 M) |
| TNON | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (753 K) | (7.7 M) | (19.1 M) | (15.6 M) | (14.8 M) |
| NAOV | (723 K) | (723 K) | (1.3 M) | (2 M) | (2.6 M) | (2.9 M) | (2.8 M) | (5 M) | (4.2 M) | (5.8 M) | (4.3 M) | (14.3 M) | (5.4 M) | (3.7 M) | (3.9 M) |
| SINT | (23.8 M) | (23.8 M) | (35 M) | (8.3 M) | (32.6 M) | (23.9 M) | (16.6 M) | (16.6 M) | (8.7 M) | (4.8 M) | (7.3 M) | (9.8 M) | (16.5 M) | (8.3 M) | (8.7 M) |
| RSLS | (1.9 M) | (26 M) | (23.5 M) | (25.8 M) | (26.1 M) | (25.5 M) | (23.4 M) | (33.8 M) | (81.2 M) | (74.2 M) | (21.6 M) | (61.9 M) | (46.2 M) | (11.4 M) | (12 M) |
Bone Biologics Corp and related stocks such as Bluejay Diagnostics, Talis Biomedical Corp, and Nuwellis Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Bone Biologics Corp financial statement analysis. It represents the amount of money remaining after all of Bone Biologics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Bone Biologics Corp | BBLG |
Specialization | Health Care, Health Care Equipment & Services |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.3
Check out Bone Biologics Performance and Bone Biologics Correlation. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Bone Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.